Sign In
Last checked at 
25 Feb 2020 07:00
Renalytix AI plc
("RenalytixAI", the "Company" or the "Group")
Conference attendance
CEO speaking at Cowen 40th Annual Health Care Conference
Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference, which runs from the 1-4 March 2020, hosted at Boston Marriott Copley Place, Boston, USA.
The conference brings together top institutional investors and leading companies operating in the Health Care space.
James McCullough, CEO of Renalytix, will be presenting on Tuesday 3 March at 8.40am - 9.10am in Simmons, 3rd Floor.
The presentation will be made available on the Company's website shortly after here:
https://renalytixai.com/investors/company-presentation/ and no new material or trading information will be provided.
For further information, please contact:
Renalytix AI plc | www.renalytixai.com | |||
James McCullough, CEO | Via Walbrook PR | |||
|
| |||
Stifel (Nominated Adviser & Joint Broker) | Tel: 020 7710 7600 | |||
Alex Price / Jonathan Senior / Ben Maddison |
| |||
|
| |||
N+1 Singer (Joint Broker) | Tel: 020 7496 3000 | |||
Aubrey Powell / George Tzimas (Corporate Finance) |
| |||
Tom Salvesen / Mia Gardner (Corporate Broking) |
| |||
|
| |||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com
| |||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |||
About Kidney Disease
Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
For more information, visit renalytixai.com
Follow the stocks
